



# Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation


## SUPPLEMENTARY FIGURES




Supplementary Figure S1: Comparison of OS according to line of treatment for anti-angiogenic agents.




Supplementary Figure S2: Comparison of OS according to line of treatment for all examined pathways.




Supplementary Figure S3: Comparison of OS according to platinum status.




Supplementary Figure S4: Comparison of OS according to maintenance phase.




Supplementary Figure S5: Comparison of PFS according to line of treatment for all examined pathways.



Supplementary Figure S6: Comparison of PFS according to platinum status.




Supplementary Figure S7: Comparison of PFS according to maintenance phase.




Supplementary Figure S8: Comparison of RR according to each examined pathway.







Supplementary Figure S9: Expression levels of VEGFA in EOC dataset.



Supplementary Figure S10: Expression levels of CD31 in EOC dataset.




Supplementary Figure S11: Comparison of OS according to maintenance phase for anti-angiogenic agent.




Hazard Ratio OS


Supplementary Figure S12: Comparison of OS according to platinum status for anti-angiogenic agent.




Supplementary Figure S13: Comparison of OS according to platinum status for anti-EGFR agent.




Supplementary Figure S14: Comparison of OS according to line of treatment for miscellaneous.



Supplementary Figure S15: Comparison of OS according to platinum status for miscellaneous.




Supplementary Figure S16: Comparison of PFS according to line of treatment for anti-angiogenic agents.




Supplementary Figure S17: Comparison of PFS according to maintenance phase for anti-angiogenic agents.







Supplementary Figure S18: Comparison of PFS according to platinum status for anti-angiogenic agents.



Supplementary Figure S19: Comparison of PFS according to platinum status for anti-EGFR agents.




Supplementary Figure S20: Comparison of PFS according to line of treatment for miscellaneous.




Hazard Ratio PFS

Supplementary Figure S21: Comparison of PFS according to maintenance phase for miscellaneous.




Hazard Ratio PFS


Supplementary Figure S22: Comparison of PFS according to platinum status for miscellaneous.



Supplementary Figure S23: Comparison of RR according to line of treatment for anti-angiogenic agents.




Supplementary Figure S24: Comparison of RR according to maintenance phase for anti-angiogenic agents.




Supplementary Figure S25: Comparison of RR according to platinum status for anti-angiogenic agents.






Supplementary Figure S26: Comparison of RR according to platinum status for anti-EGFR agents.



Supplementary Figure S27: Comparison of RR according to line of treatment for miscellaneous.



ODDS RATIO RR

Supplementary Figure S28: Comparison of RR according to platinum status for miscellaneous.